Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROGESTIN 1.5/30 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Acne vulgaris (off-label, for women who desire contraception and have not responded to topical therapy),Dysmenorrhea (off-label),Endometriosis (off-label),Menorrhagia (off-label),Functional ovarian cysts (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-19 hours. Steady-state reached within 5-7 days.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Norethindrone acetate is deacetylated to norethindrone, primarily metabolized via cytochrome P450 3A4 (CYP3A4) to reduced metabolites, sulfates, and glucuronides. Ethinyl estradiol is metabolized primarily by CYP3A4, undergoes hydroxylation, and undergoes conjugation (glucuronidation and sulfation). Both undergo enterohepatic recirculation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: ~50-60% (primarily as glucuronide conjugates of ethinyl estradiol and norethindrone); Fecal: ~40-50% (via biliary elimination)
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Norethindrone: 90-95% bound to SHBG and albumin; Ethinyl estradiol: 95-98% bound to albumin, with 2-5% free.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Norethindrone: 3-5 L/kg; Ethinyl estradiol: 2-4 L/kg. High Vd indicates extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: Norethindrone ~64-75%; Ethinyl estradiol ~45-60% due to first-pass metabolism.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment is required for patients with renal impairment. However, because of potential fluid retention, use with caution in patients with renal dysfunction.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in patients with acute liver disease or hepatocellular carcinoma. For Child-Pugh class A: use with caution; class B or C: not recommended due to potential for impaired hormone metabolism.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Safety and effectiveness in pediatric patients under 18 years have not been established. Not indicated for use before menarche.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use in postmenopausal women. No specific dosing recommendations in elderly; evaluate risk-benefit considering comorbidities (e.g., cardiovascular disease).
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events (thrombophlebitis, venous thromboembolism, stroke, myocardial infarction) from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (venous thromboembolism, arterial thrombosis), stroke, myocardial infarction, especially in smokers >35 years. Hepatic neoplasia (benign and malignant), hypertension, gallbladder disease, carbohydrate/lipid effects, headache/migraine exacerbation, visual disturbances (retinal thrombosis). Breakthrough bleeding/spotting. Hepatic enzyme induction (e.g., rifampin) may reduce contraceptive efficacy.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Active or history of thrombophlebitis or thromboembolic disorders. Cerebrovascular or coronary artery disease. Known or suspected pregnancy. Undiagnosed abnormal uterine bleeding. Known or suspected breast carcinoma or other estrogen-/progestin-sensitive neoplasia. Hepatic adenoma or carcinoma. Jaundice or cholestatic jaundice of pregnancy, or history of jaundice with prior oral contraceptive use. Acute or chronic hepatocellular disease with abnormal liver function. Heavy smoking (≥15 cigarettes/day) in women >35 years. Hypersensitivity to any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but no specific restriction. Consistent dietary habits are recommended to avoid cycle irregularities.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
First trimester: An increased risk of cardiovascular defects and oral clefts following first-trimester exposure to oral contraceptives has been suggested but not confirmed. Norethindrone and ethinyl estradiol are not recommended during pregnancy. If pregnancy occurs, the drug should be discontinued. Second and third trimesters: Exposure to estrogens and progestins may cause fetal harm, including urogenital abnormalities in female fetuses (e.g., hypospadias in males, clitoral enlargement, labial fusion in females). Use is contraindicated during known or suspected pregnancy.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Small amounts of oral contraceptive steroids (including norethindrone and ethinyl estradiol) are excreted in breast milk. The M/P ratio is approximately 0.5 for norethindrone and 0.01–0.02 for ethinyl estradiol. Use during lactation may decrease milk production and quality. Not recommended for use in nursing mothers until weaning is complete. Alternative methods of contraception should be considered.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dosing adjustment is applicable as the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) are not relevant since use is contraindicated. Inadvertent exposure should prompt discontinuation and evaluation.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
MICROGESTIN 1.5/30 (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) is a monophasic combined oral contraceptive. Its progestin component has mild androgenic activity, which may benefit some women with acne. Bleeding irregularities are common in the first 3 cycles. Counsel patients that missing pills increases pregnancy risk; strict adherence is critical. Evaluate baseline blood pressure and consider stopping if migraine with aura develops. Liver enzyme inducers (e.g., rifampin, certain anticonvulsants) may reduce efficacy.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time to maintain steady hormone levels.,If you miss a pill, refer to the package insert: take the missed pill as soon as remembered and use backup contraception (e.g., condoms) for 7 days.,Common side effects include nausea, breast tenderness, and spotting; these often improve after 3 cycles.,Smoking increases risk of serious cardiovascular side effects, especially if over 35 years old and smoking 15+ cigarettes daily.,Seek emergency care for leg pain/swelling, sudden severe headache, chest pain, or vision changes (possible blood clot or stroke).
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROGESTIN 1.5/30 vs ALTAVERA, answered by our medical review team.
MICROGESTIN 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROGESTIN 1.5/30 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROGESTIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROGESTIN 1.5/30 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROGESTIN 1.5/30 is classified as Category C. First trimester: An increased risk of cardiovascular defects and oral clefts following first-trimester exposure to oral contraceptives has been suggested but not confirmed. Norethi. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.